Delta Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Delta Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$223K	Buy	+435	New	+$203K	0.05%	230

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Delta Financial Group's VRTX Position: Q1 2025 in Review

Delta Financial Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2025: 435 shares worth $223K. The stake represents 0.05% of the portfolio and ranks #230 among its holdings.

1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Delta Financial Group held 435 shares of Vertex Pharmaceuticals worth $223K as of Q1 2025.
Vertex Pharmaceuticals was a new Delta Financial Group position in Q1 2025.
Vertex Pharmaceuticals made up 0.05% of Delta Financial Group's portfolio in Q1 2025, its #230 holding.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Delta Financial Group's 13F filing for Q1 2025, filed 9 May 2025.